Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the
normal development of several endoderm-derived organs, including the prostate gland …

The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …

Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …

The discovery of numerous noncoding RNA (ncRNA) transcripts in species from yeast to
mammals has dramatically altered our understanding of cell biology, especially the biology …

Through a prospective clinical sequencing program for advanced cancers, four index cases
were identified which harbor gene rearrangements of FGFR2, including patients with …